Floatz logo

MNPR-101-DFO-89Zr

Urothelial Carcinoma

Monopar TherapeuticsPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

166 Active assets in the Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB

View all 50 →

Same molecule, other indications

MNPR-101-DFO-89Zr is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
urinary bladder carcinomaDormant
C
Indicative ·
39 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →